Abstract: This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD.

Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.

Abstract: The present invention relates to: Compounds of formula (I) consisting of a cyclic polymer core A and groups -L-X attached to said core A-(L-X)n (I) wherein A denotes a cyclic polymer which is comprised of 3 or 4 identical monomers which are connected by amide bonds; L may be present or not and if present is that same or different and denotes a linker moiety, X is the same or different and denotes a chelator; and n denotes an integer of 3 or 4; Compound of formula (II) consisting of a cyclic polymer core A and groups -L-X? attached to said core A-(L-X?)n (H) wherein A denotes a cyclic polymer which is comprised of 3 or 4 identical monomers which are connected by amide bonds; L may be present or not and if present is that same or different and denotes a linker moiety, X is the same or different and denotes a paramagnetic chelate consisting of a chelator X and a paramagnetic metal ion M; and n denotes an integer of 3 or 4; And compositions comprising compounds of formula (II) and their use as contrast agents in

Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.

Abstract: The present invention relates to novel linear polymers, compositions comprising said polymers and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and magnetic resonance spectroscopy (MRS).

Abstract: The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.

Abstract: The present invention relates to methods and reagents for [18F]-fluorination, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET). Thus, a compound of formula 18F-(Linker)-SH, such as a compound of formula (IV), (V), or (VI): may be reacted with an activated peptide as a means for 18F-labelling.

Abstract: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.

Abstract: A contrast agent of formula I: V-L-R (I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linear or branched amino acid-comprising biomodifier or linker moiety, and R is a reporter moiety detectable in in vivo imaging of a human or animal body.

Abstract: The invention relates to in vivo imaging agents, specifically radiolabelled insulin derivatives of formula (III); wherein X is —CO—NH—, —NH—, —O—, —NHCONH—, or —NHCSNH—, and is preferably —CO—NH—, —NH— or —O—; Y is H, alkyl or aryl substituents; R* is a radiolabel moiety suitable for detection by SPECT or PET; and methods for preparing the same as well as their use in in vivo imaging methods.

Abstract: The present invention relates to a process for the manufacture of targeting liposomes comprising vector compounds conjugated to the hydrophilic part of modified phospholipids. The present invention provides the modified phospholipids and liposomes containing said modified phospholipids.

Abstract: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.

Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.

Abstract: An aligned dual damascene opening structure, comprising the following. A structure having a metal structure formed thereover. A patterned layer stack over the metal structure; the layer stack comprising, in ascending order: a patterned bottom etch stop layer; a patterned lower dielectric material layer; a patterned middle etch stop layer; and a patterned middle dielectric material layer; the lower and middle dielectric layers being comprised of the same material. An upper trench opening in the patterned bottom etch stop layer and the patterned lower dielectric material layer; and a lower via opening in the patterned middle etch stop layer and the patterned middle dielectric material layer. The lower via opening being in communication with the upper trench opening. Wherein the upper trench opening and the lower via opening comprise an aligned dual damascene opening.

Abstract: The present invention relates to methods and reagents for [18F]-fluorination, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET). Thus, a compound of formula 18F-(Linker)-SH, such as a compound of formula (IV), (V), or (VI): 18F—(CH2CH2O)n—(CH2)m—SH ??(IV) 18F—(CH2)p—SH ??(V) may be reacted with an activated peptide as a means for 18F-labelling.

Abstract: The invention relates to new peptide-based compounds and their use in diagnostic optical imaging techniques. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labelled with at least one cyanine dye reporter and may be used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases.

Abstract: The invention relates to compounds suitable for use in an imaging agent said imaging agent showing an improved pharmacokinetic profile.

Abstract: The invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

Abstract: A method of forming one or more capacitors on or in a substrate and a capacitor structure resulting therefrom is disclosed. The method includes forming a trench in the substrate, lining the trench with a first copper-barrier layer, and substantially filling the trench with a first copper layer. The first copper layer is substantially chemically isolated from the substrate by the first copper-barrier layer. A second copper-barrier layer is formed over the first copper layer and a first dielectric layer is formed over the second copper-barrier layer. The dielectric layer is substantially chemically isolated from the first copper layer by the second copper-barrier layer. A third copper-barrier layer is formed over the dielectric layer and a second copper layer is formed over the third copper-barrier layer. The second copper layer is formed in a non-damascene process.

Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.